Publicaciones en colaboración con investigadores/as de University of Milan (13)

2007

  1. Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical stimulation

    Amino Acids, Vol. 32, Núm. 3, pp. 323-332

2005

  1. Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels

    Amino Acids

2003

  1. Neuronal sensitization and its behavioral correlates in a rat model of neuropathy are prevented by a cyclic analog of orphenadrine

    Journal of Neurotrauma, Vol. 20, Núm. 6, pp. 593-601

2002

  1. Nefopam, an analogue of orphenadrine, protects against both NMDA receptor-dependent and independent veratridine-induced neurotoxicity

    Amino Acids

2001

  1. Novel effect of nefopam preventing cGMP increase, oxygen radical formation and neuronal death induced by veratridine

    Neuropharmacology, Vol. 41, Núm. 8, pp. 935-942

1985

  1. Evaluation of hypothalamic dopaminergic function by neuropharmacologic means in aged women

    Journal of Neural Transmission, Vol. 64, Núm. 3-4, pp. 199-210

  2. Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia

    Journal of Endocrinological Investigation: Official Journal of the Italian Society of Endocrinology, Vol. 8, Núm. 1, pp. 35-40

1984

  1. DYNAMIC TESTING OF PROLACTIN AND GROWTH-HORMONE SECRETION IN PATIENTS WITH NEUROENDOCRINE DISORDERS

    ACTA ENDOCRINOLOGICA, Vol. 107, Núm. 2, pp. 155-163

  2. Hypothalamic neurotransmitter function in experimentally induced hyperprolactinemia

    Brain Research, Vol. 324, Núm. 2, pp. 233-241

  3. In vivo supersensitivity of the anterior pituitary of old female rats to dopaminergic inhibition of prolactin secretion

    Gerontology, Vol. 30, Núm. 6, pp. 345-349

1983

  1. Prolactin-Lowering and- Releasing Drugs: Mechanisms of Action and Therapeutic Applications

    Drugs, Vol. 25, Núm. 4, pp. 399-432

1982

  1. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease

    Acta Endocrinologica, Vol. 99, Núm. 3, pp. 344-351

1981

  1. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease

    Journal of Neurology Neurosurgery and Psychiatry, Vol. 44, Núm. 12, pp. 1116-1123